Recurrent Plasmodium vivax malaria due to dose-dependent primaquine resistance: A case report

Abstract

The ability of Plasmodium vivax to relapse is a challenge to its management. Primaquine is the only drug licensed for the eradication of hypnozoites. We report the case of a non-immune traveller, who required high dosage primaquine treatment to obtain radical cure of vivax malaria, emphasizing the importance of country-specific and weight-based dosing of primaquine.

Keywords::

• Plasmodium vivax
• recurrence
• primaquine
• resistance
• malaria

Declaration of interest: None. The authors report no conflict of interest. The authors alone are responsible for the content and writing of the paper.